Supplementary Figure S3 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

This is a RCT study (also classified as: Phase 2).

Key Points

Overall clinical outcomes varied significantly based on treatment administered and HPV status.
The randomized clinical trial tested two treatment combinations with unique effects on patient outcomes.
Treatment with durvalumab showed a different response compared to the combination of durvalumab plus tremelimumab.
Findings suggest that HPV status significantly influences the clinical outcomes in head and neck cancer patients.

Randomized clinical trial assessed outcomes in head and neck squamous cell carcinoma, highlighting HPV's role.

No takes yet. Share an insight, caveat, or question.

Kim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share